A phase I study of tipifarnib in combination with imatinib mesylate (IM) for patients (Pts) with chronic myeloid leukemia (CML) in chronic phase (CP) who failed IM therapy.

被引：0
|
作者：
Cortes, J
Garcia-Manero, G
O'Brien, S
Hernandez, I
Rackoff, W
Faderl, S
Thomas, D
Ferrajoli, A
Talpaz, M
Kantarjian, H
机构：
[1] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA
[2] Johnson & Johnson Pharmaceut Res & Dev, LLC, Titusville, NJ USA
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1011
引用
收藏
页码：289A / 289A
页数：1
相关论文
共 50 条
  • [41] Imatinib mesylate in newly diagnosed patients of chronic myeloid leukemia chronic phase: A comparative study
    Jacob, L. A.
    Bapsy, P. P.
    Govindbabu, K.
    Lokanatha, D.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [42] Ponatinib As Initial Therapy For Patients With Chronic Myeloid Leukemia In Chronic Phase (CML-CP)
    Cortes, Jorge E.
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Quintas-Cardama, Alfonso
    Ravandi, Farhad
    Gachimova, Evguenia
    Estrov, Zeev
    Jabbour, Elias
    O'Brien, Susan
    Kantarjian, Hagop
    BLOOD, 2013, 122 (21)
  • [43] Ponatinib As Frontline Therapy for Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Jain, Preetesh
    Kantarjian, Hagop M.
    Jabbour, Elias
    Borthakur, Gautam
    Pemmaraju, Naveen
    Daver, Naval
    Gachimova, Evguenia
    Ferrajoli, Alessandra
    Kornblau, Steven M.
    Ravandi, Farhad
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2014, 124 (21)
  • [44] Dasatinib as initial therapy for patients with chronic myeloid leukemia (CML) in early chronic phase (CP)
    Pemmaraju, Naveen
    Kantarjian, Hagop
    O'Brien, Susan
    Luthra, Raja
    Jabbour, Elias
    Quintas-Cardama, Aflonso
    Borthakur, Gautam
    Ravandi, Farhad
    Burton, Elizabeth
    Walker, Brenda
    Cortes, Jorge
    CANCER RESEARCH, 2011, 71
  • [45] Patients (Pts) with Ph plus Chronic, Myeloid Leukemia In Chronic Phase (CML-CP) with a Suboptimal Molecular Response to Imatinib (IM) Can Achieve Deeper Responses When Switched to Nilotinib.
    Miller, Carole
    Ailawadhi, Sikander
    Jillella, Anand P.
    Radich, Jerald P.
    DeAngelo, Daniel J.
    Goldberg, Stuart L.
    Williams, Denise
    Lin, Felice P.
    Akard, Luke Paul
    BLOOD, 2010, 116 (21) : 950 - 950
  • [46] Impact of Treatment with Frontline Nilotinib (NIL) vs Imatinib (IM) on Sustained Deep Molecular Response (MR) in Patients (pts) with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP)
    Hochhaus, Andreas
    Saglio, Giuseppe
    Hughes, Timothy P.
    Larson, Richard A.
    Taningco, Lilia
    Deng, Weiping
    Menssen, Hans D.
    Kantarjian, Hagop M.
    BLOOD, 2015, 126 (23)
  • [47] ENESTND 5-YEAR FOLLOW-UP: CONTINUED BENEFIT OF FRONTLINE NILOTINIB (NIL) COMPARED WITH IMATINIB (IM) IN PATIENTS (PTS) WITH CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP)
    Hughes, T. P.
    le Coutre, P. D.
    Jootar, S.
    Reiffers, J.
    Turkina, A. G.
    Saglio, G.
    Hochhaus, A.
    Kantarjian, H. M.
    Kemp, C.
    Deng, W.
    Menssen, H. D.
    Larson, R. A.
    HAEMATOLOGICA, 2014, 99 : 236 - 237
  • [48] BELA trial update: Bosutinib (BOS) versus imatinib (IM) in patients (pts) with newly diagnosed chronic phase chronic myeloid leukemia (CP CML) after 30 months of follow-up.
    Gambacorti-Passerini, Carlo
    Lipton, Jeffrey Howard
    Tee, Goh Yeow
    Casado, Luis Felipe
    Zaritskey, Andrey
    le Coutre, Philipp D.
    Duvillie, Ladan
    Pavlov, Dmitri
    Countouriotis, Athena Maria
    Byrne, Jennifer
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib
    Cortes, Jorge
    Jabbour, Elias
    Daley, George Q.
    O'Brien, Susan
    Verstovsek, Srdan
    Koller, Charles
    Zhu, Yali
    Statkevich, Paul
    Kantarjian, Hagop
    CANCER, 2007, 110 (06) : 1295 - 1302
  • [50] Phase II trial of dasatinib (DAS) in pediatric patients (pts) with chronic myeloid leukemia in chronic phase (CML-CP).
    Gore, Lia
    Kearns, Pamela
    Lee, Maria Lucia
    De Souza, Carmino Antonio
    Bertrand, Yves
    Hijiya, Nobuko
    Stork, Linda C.
    Chung, Nack-Gyun
    Cardenas-Cardos, Rocio
    Saikia, Tapan
    Fagioli, Franca
    Seo, Jong-Jin
    Landman-Parker, Judith
    Lancaster, Donna
    Place, Andrew E.
    Rabin, Karen R.
    Sacchi, Mariana
    Swanink, Rene
    Zwaan, Michel
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
12345